公开(公告)号：US20200261577A1

公开(公告)日：2020-08-20

申请号：US16830461

申请日：2020-03-26

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit SAGI ,  Dalit TALMI-FRANK ,  Inna SOLOMONOV ,  Ido AMIT

IPC: A61K39/395 ,  A61K45/06 ,  A61K31/351 ,  A61K31/196 ,  C07K16/40 ,  A61K31/215

Abstract: A method of treating or preventing a disease associated with a secondary infection in a subject infected with a pathogen is provided. The method comprises administering to the subject a therapeutically effective amount of an anti-pathogenic agent directed towards the pathogen and a therapeutically effective amount of an agent which down-regulates at least one extracellular matrix-associated polypeptide.

公开(公告)号：US20240398906A1

公开(公告)日：2024-12-05

申请号：US18804150

申请日：2024-08-14

Applicant: Yeda Research and Development Co. Ltd. ,  Ramot at Tel-Aviv University Ltd.

Inventor： Irit SAGI ,  Nikolaos A. AFRATIS ,  Inna SOLOMONOV ,  Carmit LEVY ,  Shivang PARIKH

IPC: A61K38/44 ,  A61K38/17 ,  A61K45/06 ,  A61P35/00

Abstract: A method of treating a cancer which is characterized by an up-regulation of expression of lysyl oxidase (LOX) and heat shock protein 70 (HSP70) is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a propeptide of lysyl oxidase (LOX), said polypeptide being devoid of LOX catalytic activity, wherein said polypeptide binds to both LOX and heat shock protein 70 (HSP70) with a EC50 of less than 100 nM.

公开(公告)号：US20180028650A1

公开(公告)日：2018-02-01

申请号：US15549161

申请日：2016-02-09

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Irit SAGI ,  Dalit TALMI - FRANK ,  Inna SOLOMONOV ,  Ido AMIT

IPC: A61K39/395 ,  A61K31/196 ,  A61K31/215 ,  C07K16/40 ,  A61K31/351

CPC classification number: A61K39/3955 ,  A61K31/196 ,  A61K31/215 ,  A61K31/351 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/40 ,  A61K2300/00

Abstract: A method of treating or preventing a disease associated with a secondary infection in a subject infected with a pathogen is provided. The method comprises administering to the subject a therapeutically effective amount of an anti-pathogenic agent directed towards the pathogen and a therapeutically effective amount of an agent which down-regulates at least one extracellular matrix-associated polypeptide.